アルツハイマー病の進行を予測する転倒
Audrey A Keleman1,2,3, Melody Li4, Julie K Wisch4
1Program in Occupational Therapy, Washington University School of Medicine, St. Louis, Missouri, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|February 7, 2026
まとめ
認知機能が正常な高齢者における転倒は、アルツハイマー病(AD)の進行が速いことを示す可能性がある。前臨床ADおよび転倒のある個人は、軽度の認知症への進行が最も速かった。
科学分野:
- 神経科学
- 老年医学
- 神経学
背景:
- 前臨床アルツハイマー病(AD)は、認知機能が正常な個人(Clinical Dementia Rating [CDR] = 0)における脳のアミロイド蓄積を伴う。
- 転倒のような加齢に伴う併存障害と重なるため、健康な老化と前臨床ADを区別することは困難である。
- 転倒は高齢者によく見られ、神経学的な変化の早期指標となる可能性がある。
研究 の 目的:
- 前臨床アルツハイマー病における転倒と認知機能低下との関連を調査すること。
- 転倒が前臨床ADから軽度認知症(CDR 1)への進行を加速させるかどうかを判断すること。
主な方法:
- 前臨床ADの状態と転倒の有無に基づいて、参加者は4つのグループに分類された:前臨床AD-転倒-、前臨床AD-転倒+、前臨床AD+転倒-、および前臨床AD+転倒+。
- ベースライン時に転倒を1年間監視し、前臨床ADの状態(アミロイド)を評価した。
- 認知機能が正常な(CDR 0)高齢者125人を中央値10年間追跡した縦断コホート研究。
主要な成果:
- 前臨床AD+転倒+群はCDR 1への進行が最も速かった。
- 前臨床ADがなく転倒もなかった個人(前臨床AD-転倒-)が最も進行が遅かった。
- 前臨床ADはあるが転倒はなかった(前臨床AD+転倒-)個人と、前臨床ADはないが転倒はあった(前臨床AD-転倒+)個人では、進行率は同様であった。
結論:
- 転倒は、アルツハイマー病の認知症進行の加速の早期指標となる可能性がある。
- この関連は、転倒がAD病理に関連する根本的な運動および歩行機能障害を反映している可能性を示唆している。
- 認知機能が正常な個人における転倒リスクを特定することは、AD進行の早期発見に役立つ可能性がある。
関連する概念動画
Psychosis: Goals of Pharmacotherapy
706
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
706
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Huntington Disease l: Introduction
110
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
110


